On November 14, 2012, the Board of Directors of Pharmacyclics, Inc. (the "Company") approved a change in the Company's fiscal year end from June 30 to December 31, effective December 31, 2012. As a result of this change, the Company expects to file a transition report on Form 10-KT for the six months period from June 30, 2012 to December 31, 2012. The Company's next fiscal year will end on December 31, 2013.

The 2012 Annual Meeting was held on November 9, 2012. The following three matters were put forth to the stockholders to be voted on: (1) the election of seven (7) directors to serve until the 2013 annual meeting and until their successors are duly elected and qualified; (2) a proposal to consider and approve an advisory resolution regarding the compensation of the Company's named executive officers; and (3) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2013. All directors were elected, proposal two was approved and proposal three was ratified.

The total number of shares of Common Stock voted in person or by proxy at the 2012 Annual Meeting was 65,571,808, representing 93.85% of the 69,570,808 shares outstanding and entitled to vote at the 2012 Annual Meeting. Each of the matters submitted to a vote of the Company's stockholders at the 2012 Annual Meeting was approved by the requisite vote of the Company's stockholders. Set forth below is the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes as to each such matter, including a separate tabulation with respect to each nominee for director, as applicable.

                                               Broker
Nominee                  For        Withheld   Non-votes
Robert F. Booth, Ph.D.   55,517,099    572,827 9,205,539
Kenneth A. Clark         55,314,230    775,696 9,205,539
Robert W. Duggan         55,848,981    240,945 9,205,539
Eric H. Halvorson        56,008,855     81,071 9,205,539
Minesh P. Mehta, M.D.    44,600,182 11,849,744 9,205,539
David D. Smith, Ph.D.    56,036,082     53,844 9,205,539

Richard A. van den Broek 53,439,932  2,649,994 9,205,539



                                                           Broker
Proposal                     For        Against  Abstain   Non-Votes
Approval of an advisory
resolution regarding the
compensation of the
Company's named executive
officers                     55,869,968  188,595    25,865 9,205,539
Ratification of the
appointment of
PricewaterhouseCoopers LLP   64,940,388  327,576    22,003         -